U.S. SECURITIES ~~AND EXCHANGE COMMISSION~~

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED ~~NOVEMBER~~MAY ~~30, 2011~~31.

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ~~____~~__________ TO ~~_____~~__________

COMMISSION FILE NUMBER: 333-158560

BIOSTEM U.S. CORPORATION

Exact Name of Company as Specified in Its Charter)

Nevada		80-0324801
(State or Other Jurisdiction of Incorporation)		(I.R.S. Employer or Organization Identification No.)

~~1266~~ 13555 ~~Turner~~Automobile ~~Street~~and Umberton Road, Suite 110 Clearwater, FL ~~33756~~33762 (~~800~~727) ~~883~~446-~~4249~~5000

(Address of Principal Executive Offices, Company’s Telephone Number)

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the Company is a large accelerated filer, an accelerated file, non-accelerated filer, or a smaller reporting company.

Large accelerated filer	o	Accelerated filed	o
Non-accelerated filer	o	Smaller reporting company	x

Indicate by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of ~~January~~July 1712, 2012, there were 85280,~~136~~490,~~967~~856 shares of Common Stock of the issuer outstanding.

BIOSTEM U.S. CORPORATION.

~~FORM~~Form 10-Q

		PAGE
Part 1. FINANCIAL INFORMATION
PART 1	FINANCIAL INFORMATION
			Page
Item 1	Financial Statements
	Balance Sheets as of November 30, 2011 and February 28, 2011 (Unaudited)	4
	Balance Sheets as of May 31, 2012 and February 29, 2012 (Unaudited)			3
	Statements of Operations for the Three and Nine Months Ended November 30, 2011 and 2010 (Unaudited)	5
	Statements of Operations for the Three Months Ended May 31, 2012 and 2011 (Unaudited)			4
	Statements of Cash Flows for the Nine Months Ended November 30, 2011 and 2010 (Unaudited)	6
	Statements of Cash Flows for the Three Months Ended May 31, 2012 and 2011(Unaudited)			5
	Notes to Financial Statements(Unaudited)	7		6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10		8
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	14		10
Item 4.T	Controls and Procedures	14		11
PART II.	OTHER INFORMATION
Part II. OTHER INFORMATION
Item 1	Legal Proceedings	16		12
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21		17
Item 3	Defaults Upon Senior Securities	22		17
Item 4	Removed and Reserved	22		17
Item 5	Other Information	22		17
Item 6	Exhibits	22		17

FORWARD LOOKING STATEMENTS

Statements made in this Form 10-Q that are not historical or current facts are forward-looking statements. These statements often can be identified by the use of terms such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “approximate” or “continue,” or the negative thereof. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management’s best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. Among the factors that could cause actual results to differ materially from the forward-looking statements are the following: the Company’s ability to obtain necessary capital, the Company’s ability to meet anticipated development timelines, the Company’s ability to protect its proprietary technology and knowhow; the Company’s ability to identify and develop a network of physicians, the Company’s ability to establish a global market, clinical trial results, the Company’s ability to successfully consummate future acquisitions and such other risk factors identified from time to time in the Company’s reports filed with the Securities and Exchange Commission, including those filed with this Form 10-Q quarterly report. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

PART I

ITEM 1: FINANCIAL STATEMENTS

BIOSTEM U.S. CORPORATION

Balance Sheets

(Unaudited)

	November 30,			February 28,
	May 31,			February 29,
	2011			2011
	2012			2012
ASSETS
Current assets
Cash	$	23,~~491~~981		$	~~287~~4,~~126~~202
Inventory		24,396			24,720
Prepaid		11,702			11,702
Prepaid		4,559			-
Total current assets		15,683			15,904
Total current assets		31,446			311,846
Total assets	$	15,683		$	15,904
Non-current assets
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Assets held for return to related party		-			10,500
Total assets	$	31,446		$	322,346
LIABILITIES AND STOCKHOLDERS’ EQUITY(DEFICIT)
Current liabilities
Accounts payable and accrued expense	$	5873,~~855~~282		$	879,~~442~~147
Accrued consulting		45,000			-
Note payable – related party		225,000			-
Advances-third party		7,164			7,164
Advances – related parties		14,~~860~~007			484,~~759~~007
Total current liabilities		~~112~~309,~~879~~453			6490,~~365~~318
Stockholders’ equity (deficit)
Stockholders’ deficit
Common stock, par value $0.001
authorized 200,000,000 shares,
authorized 600,000,000 shares,
issued and outstanding 85,056,952
issued and outstanding 280,490,856
as November 30, 2011 and 120,160,000
as May 31, 2012 and February 28, 2012, respectively		280,491			280,491
February 28, 2011 respectively		85,057			120,160
Additional paid-in capital		3,855,706			3,191,333
Additional paid-in capital		1,758,080			346,640
Accumulated deficit		(4,429,967	)		(3,546,238	)
Accumulated deficit		(1,924,570	)		(208,819	)
Total stockholders’ deficit		(293,770	)		(74,414	)
Total stockholders’ equity(deficit)		(81,433	)		257,981
Total liabilities and stockholders’ deficit	$	15,683		$	15,904
Total liabilities and stockholders’ equity (deficit)	$	31,446		$	322,346

The accompanying notes are an integral part of the unaudited financial statements

~~BISOTEM~~BIOSTEM U.S. CORPORATION

STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended						~~Nine Months Ended~~
	November 30,						November 30,
	May 31,
	2011			2010			2011			2010
	2012			2011
Revenue	$	624		$	87,670
Procedures- related party	$	552		$	-		$	91,939		$	-
Cost of goods sold		-			38,435
Product sales		100			-			2,119			-
Gross profit		624			49,235
Total revenue		652			-			94,058			-
Selling, general and administrative expenses		884,361			212,030
Cost of goods sold		-			-			38,489			-
Loss from operations		(883,737	)		(162,795	)
Gross profit		652			-			55,569			-
Other income(expense)
Selling, general and
Interest income		8			-
administrative expenses		260,507			82,651			1,771,344			97,948
Total other income(expense)		8			-
Loss from operations		(259,855	)		(82,651	)		(1,715,775	)		(97,948	)
Net loss	$	(883,729	)	$	(162,795	)
Other income(expense)
Loss per common share Basic and diluted	$	(0.00	)	$	(0.00	)
Interest income		24			-			24			-
Weighted average number of common shares outstanding		280,490,856			360,480,000
Total other income(expense)		24			-			24			-
Net loss	$	(259,831	)	$	(82,651	)	$	(1,715,751	)	$	(97,948	)
Income Loss per common share
Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.02	)	$	(0.00	)
Weighted average number
of common shares outstanding		83,854,316			113,918,240			101,590,095			83,348,364

The accompanying notes are an integral part of the unaudited financial statements

BIOSTEM U.S. CORPORATION

STATEMENTS OF CASH FLOWS

(Unaudited)

	Nine Months
	Three Months
	Ended November 30,
	Ended May 31,
	2011			2010
	2012			2011
Cash Flows From Operating Activities:
Cash flows from operating activities:
Net loss	$	(1883,~~715,751~~729	)	$	(97162,~~948~~795	)
Adjustments to reconcile net loss to
Adjustments to reconcile net loss to net cash used in operating activities:
net cash used in operating activities:
Stock based compensation		664,373			-
Asset held and returned		-			-
Stock based compensation		1,093,938			-
Debt forgiven by related party		-			-
Changes in operating assets and liabilities:
Inventory		~~324~~-			-229
Prepaid		~~(4,559~~-	)		(105,~~500~~000	)
Accounts payable and accrued expense		95(5,~~413~~865	)		5(6,~~568~~592	)
Net cash used in operating activities		(~~530~~225,~~635~~221	)		(~~102~~174,~~880~~158	)
Cash Flows From Financing Activities:
Cash flows from financing activities:
Advances		-			7,164
Notes payable – related party		225,000			-
Advances – related party		-			95,993
Net cash provided by financing activities		225,000			-
Sale of common stock		246,000			400,000
Net increase(decrease)in cash		(221	)		(174,158	)
Net cash provided by financing activities		246,000			503,157
Cash at beginning of period		4,202			287,126
Net increase(decrease)in cash		(284,635	)		400,277
Cash at end of period	$	3,981		$	112,968
Cash at beginning of period		287,126			-
Cash at end of period	$	2,491		$	400,227
Supplemental schedule of cash flow information:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

NONCASH INVESTING AND FINANCING
Stock transferred per change of control	$	-		$	20,400
Forgiveness of accounts payable – related party	$	(46,899	)	$	40,000
Return of assets –related party	$	10,500		$	-
Common stock returned and cancelled	$	12,014		$	-

The accompanying notes are an integral part of the unaudited financial statements

BIOSTEM U.S. CORPORATION

Notes to the Financial Statements

(Unaudited)

NOTE 1 - ~~ORGANIZATION~~DESCRIPTION ~~AND~~OF BUSINESS, ~~OPERATIONS~~BASIS OF PRESENTATION

The Company was incorporated as Equinox International, Inc. on November 5, 2008 in the state of Nevada. ~~Originally,~~The ~~the~~ Company planned to commence operations in the oil and gas exploration and production industry in North America. However, as previously reported, on May 5, 2010, with the goal of becoming a marketing and licensing company that would market certain regenerative medical procedures and products and license its brand and technologies to a network of medical providers (who would, in turn, provide medical procedures to their patients based on the Company’s technologies), the Company acquired from Biostem US LLC, a privately held Florida limited liability company (the “LLC”), certain assets (the “Acquired Assets”) related to hair transplant and hair regrowth procedures (the “Asset Transfer”). Specifically, the Acquired Assets consists of a hair transplant ~~process~~ and hair protocols known as the “Biostem Method” that involves the injection of autologous platelet rich plasma containing stem cells from the patient to the scalp of the patient in combination with an oral nutriceutical and the concomitant use of low-level laser therapy, which combination the Company believes helps support the healing of ~~transplanted~~transplant ~~area~~areas and increases the success of the hair transplant and hair regrowth surgery.

~~Prior~~The toaccompanying ~~the~~unaudited ~~Asset~~interim ~~Transfer,~~financial ~~Biostem~~statements USof ~~LLC acquired~~ the ~~Biostem~~Company ~~Method~~have ~~from~~been ~~Dr.~~prepared ~~Markou,~~in ~~who~~accordance ~~owns~~with ~~and~~accounting ~~operates~~principles agenerally ~~hair~~accepted ~~restoration medical clinic~~ in ~~Clearwater, FL, which he operates as Markou Medical, P.A. Prior to~~ the ~~Asset~~United ~~Transfer,~~States ~~Dr.~~of ~~Markou~~America ~~provided~~and ~~many procedures for his patients at his clinic, including (but not limited to) hair transplants based upon~~ the ~~Biostem~~rules ~~Method.~~of ~~Since~~ the ~~Asset~~Securities ~~Transfer,~~and ~~Dr.~~Exchange ~~Markou continues to provide many procedures at his clinic~~Commission, including (but not limited to) hair transplants based upon the Biostem Method. However, since the Asset Transfer, any hair transplants that he conducts based upon the Biostem Method are pursuant to a medical affiliate arrangement between Dr. Markou and ~~the~~should ~~Company,~~be ~~pursuant~~read toin ~~which~~conjunction ~~the~~with ~~Company grants Dr. Markou~~ the ~~right~~audited tofinancial ~~use~~statements ~~the processes~~ and ~~protocols~~notes ~~related~~thereto tocontained ~~the~~in ~~Biostem Method, as well as~~ the ~~Biostem tradename, and markets the hair transplant procedure on Dr. Markou~~Company’s ~~behalf,~~February ~~and~~29, in2012 ~~consideration~~Annual ~~thereof,~~Report ~~Dr.~~filed ~~Markou~~with ~~pays to~~ the ~~Company~~SEC ~~licensing and marketing fees ranging from $400 to $500 per hair transplant depending~~ on ~~the~~Form ~~number of grafts in such transplant~~10-K. ~~Pursuant~~In to the ~~medical~~opinion ~~affiliate~~of ~~agreement~~management, all ~~hair~~adjustments, ~~transplants~~consisting ~~and~~of ~~related~~normal ~~procedures~~recurring ~~are~~adjustments, tonecessary befor ~~provided~~a byfair ~~Dr.~~presentation ~~Markou~~of ~~(or~~financial ~~other~~position ~~medical~~and ~~professionals~~the ~~under~~results ~~his~~of ~~supervisions),~~operations ~~through~~for ~~his~~the ~~clinic~~interim ~~and~~periods ~~under~~presented ~~his~~have ~~supervision,~~been ~~and~~reflected ~~to his patients~~herein. The ~~agreement~~results ~~does~~of ~~not~~operations ~~prevent~~for ~~Dr.~~interim ~~Markou~~periods ~~from~~are ~~providing~~not ~~other~~necessarily ~~procedures~~indicative atof ~~his clinic, and Dr. Markou does not pay~~ the ~~Company~~results ~~any~~to ~~licensing~~be orexpected ~~marketing fees~~ for ~~these~~the ~~other~~full ~~procedures~~year. ~~The~~ ~~Company~~Notes ~~does~~to ~~not~~the ~~provide~~financial ~~hair~~statements ~~transplants~~which orwould ~~practice~~substantially ~~medicine~~duplicate orthe ~~manage~~disclosure ~~Dr.~~contained ~~Markou’s~~in ~~practice, but instead licenses~~ the ~~Biostem~~audited ~~Method~~financial ~~and~~statements ~~name~~for tothe ~~Dr.~~most ~~Markou~~recent ~~and~~fiscal ~~provides~~year ~~marketing~~end ~~(including~~February ~~radio~~29, ~~television~~2012, ~~and~~as ~~internet~~reported ~~campaigns)~~on ~~relating~~Form ~~the~~10-K, ~~Biostem~~have ~~Method~~been ~~to help drive patients to Dr~~omitted. ~~Markou’s practice.~~

~~The~~NOTE ~~Company~~2- ~~did~~GOING ~~not acquire any tangible assets from Biostem US LLC or Dr. Markou, only the intangible assets related to the Biostem Method and name.~~CONCERN

InAs ~~consideration~~shown ~~for~~in the ~~Acquired~~accompanying ~~Assets~~financial statements, ~~the~~Biostem ~~Company,~~has atan ~~the~~accumulated ~~direction~~deficit of ~~the LLC~~$4, ~~issued 20~~429,~~400,000~~967 ~~shares~~as of ~~common~~May ~~stock~~31, to2012 ~~the~~and 11incurred ~~owners~~a net loss of $883,729 for the ~~Biostem~~three USmonths ~~LLC,~~ended ~~which~~May ~~resulted~~31, in2012. Unless the ~~change~~Company ofbecomes ~~control~~profitable ofand ~~the~~increases ~~Company~~stockholders’ equity, asthese ~~the~~conditions ~~owners~~raise ofsubstantial ~~the~~doubt ~~LLC~~as ~~owned~~to ~~approximately~~Biostem’s ~~95%~~ability ofto ~~the~~continue ~~25,040,000~~as ~~shares~~a ofgoing ~~Company~~concern. ~~common~~These ~~stock~~financial ~~outstanding~~statements ~~immediately~~do ~~after~~not ~~the~~include ~~Asset~~any ~~Transfer.~~adjustments Asthat ~~the~~might ~~seller~~be ofnecessary ~~the~~if ~~Acquired~~Biostem ~~Assets~~is ~~retained~~unable ~~control~~to ofcontinue ~~the~~as ~~assets~~a ~~through~~going ~~their~~concern. ~~control~~Biostem ofcontinues ~~the~~to ~~Company~~review its expense structure, ~~the~~reviewing ~~Acquired~~costs ~~Assets~~and ~~were~~their ~~recorded~~reduction atto ~~the~~move ~~seller~~towards profitability. The Company’s ~~basis~~expenses are planned to decrease as a percentage of $0a revenue resulting in profitability and increased stockholders’ equity.

InNOTE ~~connection~~3 ~~with~~– ~~the~~SUMMARY ~~Asset~~OF ~~Transfer,~~ACCOUNTING ~~effective May 5, 2010, the Company changed its name to Biostem U.S. Corporation and increased its authorized stock to 200,000,000 shares of common stock, par value $.001 per share.~~POLICIES

~~Since~~Recently ~~the~~issued ~~Asset~~accounting ~~Transfer, the Company has discontinued its former oil and gas business and instead has begun to pursue its marketing and licensing business focused on regenerative medicine.~~pronouncements

~~The~~We ~~Company~~do ~~has~~not ~~depleted~~expect ~~its~~the ~~cash~~adoption ~~and~~of ~~will~~recently ~~require~~issued ~~significant~~accounting ~~additional~~pronouncements ~~financing~~ to ~~achieve~~have ita ~~business~~significant ~~plans~~impact ~~and~~on ~~objectives.~~our ~~Over~~results ~~the~~of ~~next 12 months~~operations, ~~the~~financial ~~Company~~position ~~anticipates~~or itcash ~~will require approximately $2,000,000~~flow. While the Company is exploring financing options, there can be no assurances that it will be able to obtain additional financing. The Company’s ability to effectuate its business plans and objectives are subject to various risks. See “Risk Factors.”

NOTE 2 – SUMMARY OF ACCOUNTING POLICIES

Revenue recognition

Biostem’s revenue is recognized pursuant to ASC 605 “Revenue Recognition.” The Company receives and recognizes the revenue from procedures performed by a related party under the licensing agreement after the procedures have been performed and the revenue has been received from the related party. Biostem sells products to its clients and the revenue from the product sales is recognized at the point of sale when the product is given to the client and the payment is made by the client.

Stock Based Compensation

The company adopted the provisions of ASC 718 requiring employee equity awards to be accounted for under the fair value method. Accordingly, share-based compensation is measured at grant or vesting date, based on the fair value of the award and is recognized as expense over the requisite employee service period. The Company estimates the fair value of share-based payments using the Black-Scholes option-pricing model for common stock options and the closing price of the company’s common stock for common share issuances.

NOTE 3- BASIS OF PRESENTATION

The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s February 28, 2011 Annual Report filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited financial statements for the most recent fiscal year end February 28, 2011, as reported on Form 10-K, have been omitted.

NOTE 4 - ADVANCES

A former director advanced the Company money for operating expenses. The director has resigned due to the change in control of the Company and is no longer a related party. As of ~~November~~May 3031, ~~2011~~2012, the outstanding balance due on this advance was $7,164. The advance is unsecured, bears no interest and is due on demand.

~~NOTE 5-RELATED PARTY TRANSACTIONS~~6

~~During~~NOTE ~~July~~5- ~~2011,~~RELATED ~~the~~PARTY Company and one of its former officers agreed that the debt due to the former officer of $46,899 is forgiven by him and assets of $10,500 which were originally paid by the former officer are to be returned to him. The asset was offset with the advance payable and the forgiveness of advance is recorded as a contribution of capital in the amount of $36,399. As part of the agreement, the former officer returned 6,806,631 shares of common stock of the Company under his possession, which were cancelled by the Company upon receipt and recorded as a contribution of capital.TRANSACTIONS

On ~~July~~March 720, ~~2011,~~2012 the ~~former~~ Company ~~President~~issued ~~and~~a ~~now~~note ~~the~~to ~~Chief~~a ~~Financial~~stockholder ~~Officer~~for ~~returned 5~~$25,~~206,631~~000 ~~shares~~which ofis ~~common~~due ~~stock,~~on ~~which~~July ~~were~~20, ~~cancelled~~2012 and ~~recorded~~bears asinterest aat ~~contribution of capital~~8%.

On ~~June~~March 1120, ~~2011,~~2012 the Company ~~entered into an employment agreement with the Chief Executive Officer of the Company and~~ issued ~~1,600,000~~a ~~shares~~note to ~~the CEO per his agreement. The shares issued vest over~~ a ~~36-month~~related ~~period~~party ~~beginning~~for ~~on June 11~~$60,000 ~~2011~~which atis ~~the~~due ~~rate~~on ofJuly 4420,~~445~~ ~~shares~~2012 ~~per~~and ~~month.~~bears ~~The~~interest ~~issued~~at ~~shares have full voting rights~~8%. ~~The Company recognized compensation expense in the amount of $342,938 as of November 30, 2011 in connection with such share issuance.~~

~~The~~On ~~Company~~April ~~maintains~~18, a2012 ~~physical~~the ~~office~~Company atissued ~~13555~~a ~~Automobile~~note ~~and~~to ~~Umberton~~a ~~Road~~related ~~Suite~~party ~~110,~~for ~~Clearwater~~$100,000 FLwhich ~~33762 that~~ is ~~leased~~due ~~from~~on ~~one~~August of18, ~~the~~2012 ~~Officers~~and ofbears ~~the~~interest ~~Company~~at 8%.

On April 13, 2012 the Company issued a note to a related party for $40,000 which is due on August 13, 2012 and bears interest at 8%.

NOTE 6~~: STOCKHOLDERS~~- EQUITY

OnDuring ~~July~~the 14quarter, ~~2011,~~ the Company ~~entered~~recognized ~~into a 24-month consulting agreement~~$400,000 in ~~consideration~~stock ~~for~~compensation ~~services~~expense ~~the~~related ~~Company~~to ~~issued~~ 1,~~000~~600,000 shares ofissued ~~restricted~~to ~~common~~the ~~stock.~~CEO ~~The shares vest~~ in ~~an equal allotment of 41,667 per month with~~ the ~~first~~prior ~~six months vesting immediately on the date of agreement~~year. The shares ~~not~~vest ~~vested~~over ~~have~~the ~~full~~term ~~voting rights unless there is a cancellation~~ of the agreement, ~~between~~36 ~~the Company and the consulting party~~months.

On July 14, 2011, the Company entered into a Consulting Agreement with NVO, LLC, ~~a California limited liability company, pursuant to which NVO will assist the Company with its business objectives, including (i) identifying, analyzing, structuring~~ and~~/or~~ negotiating business sales and/or acquisitions, (ii) assisting the Company in its corporate strategies, (iii) assisting the Company in the implementation of its business plan, and (iv) assisting the Company in the negotiation, documentation and closing of strategic alliances, partnerships and joint ventures. In consideration thereof, the Company is making certain cash payments to NVO and issued 112,000,000 shares of restricted common stock to NVO, ~~250~~3,000,000 of which vested immediately on July 14, 2011 and the balance of which vests in 18 monthly installments of 41500,~~666.67~~000 commencing on January 14, ~~2011~~2012. The ~~250~~3,000,000 shares which vested on July 14, 2011 were measured and recognized as expense during the quarter ending August 31, 2011, ~~resulting in an expense of $750,000.~~ The remaining ~~750~~9,000,000 shares will be measured and expensed at the completion of each month during the remaining 18-month vesting period based on the price of the Company’s stock price during such period, which will result in future expenses that will fluctuate based on the stock price in each future month during the vesting period. As ~~a result~~ of ~~the~~May ~~Company’s~~31, ~~light~~2012, ~~trading volume and its volatile stock price~~6,750,000 ~~the total expense associated with these~~ shares ishave ~~uncertain,~~not ~~but~~been ~~could be significant~~vested. ~~Over~~During the ~~last year~~quarter, ~~the Company’s stock price has traded between~~ $~~4.00 and $0.06. Thus~~264,373 atwas ~~the~~recognized ~~high~~as ~~end~~stock ofcompensation ~~this range, the total~~ expense ~~for~~pursuant to the ~~remaining 750,000 shares would be $3,000,000, which could have a material unfavorable impact on income from continuing operations~~agreement.

~~The~~NOTE ~~Company~~7 ~~recognized~~– ~~consulting~~COMMITMENTS ~~expense~~AND ~~in the amount of $750,000 as of November 30, 2011 in connection with its Consulting Agreement with NVO and accrued $45,000 of unpaid fees.~~CONTINGENCIES

~~During~~On May 8, 2012 the ~~period~~Company ~~ending~~signed ~~November~~a ~~30,~~consulting ~~2011,~~agreement ~~the~~with an investor relations firm. The Company ~~issued~~paid ~~637~~the firm $5,~~500~~000 ~~shares~~on ofMay ~~common~~21, ~~stock~~2012 and is committed to ~~various~~pay ~~investors~~$5,000 ~~for~~on ~~cash~~June ~~proceeds~~21. of2012 and $~~246~~5,000 ~~with~~on aJuly ~~value~~21, of2012 ~~$0.25~~plus toany ~~$0.80~~additional ~~per~~expenses ~~share~~approved by the Company.

NOTE 7:8- ~~DEVELOPMENT~~SUBSEQUENT ~~STAGE COMPANY~~EVENT

On May 23, 2012 The Company ~~from~~entered ~~inception~~into ~~through~~a ~~the~~stock ~~reporting~~purchase ~~period~~agreement ~~ending~~with ~~February~~Elco 28Securities Ltd. (“Elco”), ~~2011~~pursuant ~~was~~to ~~considered~~which athe ~~development~~Company ~~stage~~agreed ~~company.~~to Assell ofto ~~August~~Elco, 31and Elco agreed to purchase from the Company, ~~2011~~20,000,000 shares of common stock of the Company ~~has~~for ~~total~~an ~~revenues~~aggregate purchase price of $935,~~405~~000, ~~and~~000, ~~therefore,~~which ~~the~~amount ~~Company~~is ~~has~~payable ~~dropped~~in six equal monthly installments. The stock purchase agreement provides that the ~~designation~~closing of ~~development~~the ~~Stage~~forgoing ~~Company~~transaction ~~and~~will ~~started~~occur ~~operations~~on inJuly ~~hair~~1, ~~transplant~~2012 ~~business~~or ~~and~~at such other ~~regenerative~~time ~~medicine~~as ~~opportunities~~the parties may agree.

~~NOTE~~On 8:July ~~SUBSEQUENT~~1, ~~EVENT~~2012 the Company signed an affiliate contract with three clinics where the clinics will use the Company’s process in their treatment. The Clinic doctor will also serve as the Medical Director for the Biostem and one of the facilities will be the training center for future Biostem affiliates.

On ~~December~~July 125, ~~and~~2012 ~~22,~~the ~~2011~~holders the ~~Company~~notes ~~issued~~as ~~460,000~~described ~~shares~~in ofFootnote ~~Common~~5 ~~stock~~agreed to 2extend ~~individuals~~their ~~for~~notes ~~cash~~up ~~with~~to a90 ~~value~~day offrom ~~$115,000,~~date ~~($0.25~~of ~~per share)~~maturity.

~~On December 17, 2011 the Company issued 1,250,000 shares of common stock for debt with a value of $100,000 ($0.08 per share). The shares were issued to settle an outstanding balance on a contract.~~7

On December 22, 2011 the Company affected a forward split of 4 shares for each 1 share outstanding as of December 22, 2011.

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Introduction and Business Plan

The Company was incorporated as Equinox International, Inc. on November 5, 2008 in the state of Nevada. ~~Originally,~~The ~~the~~ Company planned to commence operations in the oil and gas exploration and production industry in North America. However, as previously reported, on May 5, 2010, with the goal of becoming a marketing and licensing company that would market certain regenerative medical procedures and products and license its brand and technologies to a network of medical providers (who would, in turn, provide medical procedures to their patients based on the Company’s technologies), the Company acquired from Biostem US LLC, a privately held Florida limited liability company (the “LLC”), certain assets (the “Acquired Assets”) related to hair transplant and hair regrowth procedures (the “Asset Transfer”). Specifically, the Acquired Assets consists of a hair transplant and hair regrowth process and protocols known as the “Biostem Method” that involves the injection of autologous platelet rich plasma containing stem cells from the patient to the scalp of the patient in combination with an oral nutriceutical and the concomitant use of low-level laser therapy, which combination the Company believes helps support the healing of ~~transplanted~~transplant ~~area~~and hair regrowth areas and increases the success of the hair transplant and hair regrowth surgery.

~~Prior~~The Company plans to ~~the~~enter ~~Asset~~into ~~Transfer,~~arrangements ~~Biostem~~with USother ~~LLC~~medical ~~acquired~~providers ~~the~~and ~~Biostem~~to ~~Method~~grow ~~from~~its ~~Dr.~~affiliate ~~Markou,~~network ~~who~~throughout ~~owns~~the country and ~~operates~~eventually ain ~~hair~~international ~~restoration~~markets ~~medical~~as ~~clinic~~well. inThe ~~Clearwater~~Company will not provide any medical procedures directly, FLincluding hair transplant and hair regrowth, ~~which~~but heinstead ~~operates~~through asa ~~Markou~~network ~~Medical~~of qualified medical providers, ~~P.A.~~who ~~Prior~~will toperform the ~~Asset~~medical ~~Transfer~~procedures on their patients, ~~Dr.~~using ~~Markou~~the ~~provided~~Company’s ~~many~~protocols and procedures. ~~for~~It ~~his~~is ~~patients~~expected atthat ~~his~~each ~~clinic~~such affiliated medical provider, ~~including~~will, among other things: (~~but~~1) ~~not~~be ~~limited~~granted the right to) ~~hair~~use ~~transplants~~the ~~based~~Company’s ~~upon~~procedures, protocols and trade names and the right to hold itself out as a Biostem ~~Method.~~provider; ~~Since~~(2) receive certain training and ongoing support regarding the ~~Asset~~Company’s ~~Transfer~~procedure and protocols; (3) be supplied with certain support products, ~~Dr.~~lasers ~~Markou~~and ~~continues~~other equipment necessary to ~~provide~~undertake ~~many~~the medical procedures atusing ~~his~~the ~~clinic,~~Company’s ~~including~~procedures ~~(but~~and ~~not~~protocols; ~~limited~~and to(4) ~~hair~~receive ~~transplants~~the ~~based~~benefit ~~upon~~of the ~~Biostem~~Company’s ~~Method~~marketing efforts. ~~However~~In consideration thereof, ~~since~~the affiliated medical providers will pay to the ~~Asset~~Company ~~Transfer~~certain licensing, ~~any~~marketing ~~hair~~and ~~transplants~~leasing ~~that~~fees. heIn ~~conducts~~June ~~based~~2011, ~~upon~~ the ~~Biostem~~Company ~~Method~~hired ~~are~~a ~~pursuant~~new toChief Executive Officer, Dwight Brunoehler, and appointed a ~~medical~~new ~~affiliate~~board ~~arrangement~~of ~~between~~directors. DrMr. ~~Markou~~Brunoehler devotes substantially all of his business time and efforts to the Company,. ~~pursuant~~Mr. toBrunoehler ~~which~~has reviewed the Company’s ~~grants~~systems, ~~Dr.~~protocols ~~Markou~~and processes and renegotiated the ~~right~~Company’s toagreements ~~use~~with ~~the~~its ~~processes~~former ~~and~~management. ~~protocols~~The ~~related~~Company tohas concluded that while the Biostem Method, asin ~~well~~the asform ~~the~~acquired ~~Biostem~~by ~~tradename~~the Company, is effective and ~~markets~~achieves ~~the~~positive results in hair transplant ~~procedure~~and onhair ~~Dr.~~regrowth, ~~Markou’s~~it ~~behalf,~~is ~~and,~~unlikely inthat ~~consideration~~the ~~thereof,~~Company ~~Dr.~~will ~~Markou~~be ~~pays~~able to patent the ~~Company~~current ~~licensing~~Biostem Method protocols and ~~marketing~~procedures ~~fees~~because, ~~ranging~~while ~~from~~the ~~$400~~current toBiostem ~~$500~~Method ~~per~~is ~~hair~~a ~~transplant~~unique ~~depending~~arrangement onand conglomeration of several discrete procedures (such as the ~~number~~use of ~~grafts~~low-level inlaser ~~such~~treatments ~~transplant.~~and ~~Pursuant~~PRP injections to the ~~medical~~affected ~~affiliate~~scalp ~~agreement~~areas), ~~all~~no individual procedure is novel and each has previously been used in hair ~~transplants~~transplant and ~~related~~hair regrowth procedures. ~~are~~The Company’s ability to develop a significant network of medical affiliates and its ability to charge those affiliates appropriate marketing and licensing fees could be ~~provided~~materially bynegatively Drimpacted. ~~Markou~~The Company believes its success in (ora) ~~other~~developing a robust network of medical ~~professionals~~affiliates, ~~under~~(b) ~~his~~developing ~~supervisions~~brand recognition for Biostem services and products and (c) its ability grow its regenerative medicine business depends, ~~through~~in ~~his~~part, ~~clinic~~on the value, uniqueness, protectability and ~~under~~effectiveness ~~his~~of ~~supervision~~its processes, procedures and toknowhow. ~~his~~As ~~patients.~~such, ~~The~~the ~~agreement~~Company ~~does~~is pursuing additional protocols and procedures that could be incorporated into the Biostem Method that would not ~~prevent~~only ~~Dr.~~continue ~~Markou~~to ~~from~~improve ~~providing~~its effectiveness in hair transplant and hair regrowth and other regenerative procedures, atbut ~~his~~that ~~clinic~~also would make it unique and exclusive to the Company, thus allowing it to patent and Drprotect its proprietary property. ~~Markou~~Until ~~does~~a ~~not~~patent ~~pay~~is issued, the Company ~~any~~has ~~licensing~~been orinformed ~~marketing~~that ~~fees~~its ~~for~~original ~~these~~Biostem Method can most effectively be protected with confidentiality and other ~~procedures~~appropriate agreements. The Company ~~does~~has ~~not~~entered ~~provide~~into ~~hair~~confidentiality ~~transplants~~ or ~~practice~~other ~~medicine~~similar oragreements ~~manage~~with ~~Dr.~~each ~~Markou’s~~of ~~practice,~~its ~~but~~material ~~instead~~suppliers ~~licenses~~and the ~~Biostem~~other ~~Method~~parties ~~and~~who, ~~name~~to its knowledge, have had access to ~~Dr.~~its ~~Markou~~protocols and ~~provides~~procedures, ~~marketing~~and ~~(including~~it ~~radio,~~intends ~~television~~to continue to enter into such agreements when appropriate and ~~internet~~necessary ~~campaigns)~~to ~~relating~~protect its confidential information. Furthermore, the ~~Biostem~~Company ~~Method~~intends to ~~help~~file ~~drive~~applications ~~patients~~ to ~~Dr.~~register ~~Markou’s~~its ~~practice~~trademark (Biostem) and any new protocols and procedures as they are developed and as cash flow allows.

~~During~~In ~~the~~addition three- and nine-month periods ending November 30, 2011, Dr. Markou was the Company’s only medical affiliate. Recently, Dr. Markou terminated his written contract with the Company. However, the Company believes that Dr. Markou will continue to ~~accept~~expanding ~~referrals from the Company on a case by case basis. Furthermore, the Company hopes to enter into arrangements with other medical providers~~ and toimproving ~~grow~~ its ~~affiliate~~hair ~~network~~regrowth ~~throughout~~protocols ~~the country~~ and ~~eventually in international markets as well. The Company will not provide any medical~~ procedures ~~directly~~, ~~including hair transplants, but instead through a network of qualified medical providers, such as Dr. Markou, who will perform~~ the ~~medical procedures on their patients, using the~~ Company’s ~~protocols~~also ~~and~~currently ~~procedures. It~~ is ~~expected~~working ~~that~~on ~~each such affiliated medical provider, will, among other things:~~ (1a) ~~be granted the right to use the Company’s procedures~~studying, ~~protocols~~exploring and ~~tradenames~~pursuing ~~and~~other ~~the~~regenerative ~~right~~medicine toopportunities, ~~hold itself out as a Biostem provider;~~ (2b) ~~receive~~protecting ~~certain~~its ~~training~~intellectual ~~and~~property ~~ongoing~~through ~~support~~trademark ~~regarding~~and ~~the~~patent ~~Company’s~~registrations ~~procedure~~ and ~~protocols;~~ (3c) benegotiating ~~supplied~~the ~~with~~potential ~~certain~~acquisition ~~support~~of ~~products,~~a ~~lasers~~non-U.S. ~~and~~healthcare ~~other~~company ~~equipment~~in ~~necessary~~the tostem ~~undertake~~cell ~~the~~sciences ~~medical~~business. ~~procedures~~If ~~using~~ the Company’s ~~procedures~~is ~~and~~successful ~~protocols;~~with ~~and (4) receive~~ the ~~benefit~~forgoing ~~of the Company’s marketing efforts. In consideration thereof~~objectives, the ~~affiliated~~changes ~~medical providers will pay~~ to ~~the~~its ~~Company~~current ~~certain~~products ~~licensing, marketing~~ and ~~leasing~~services ~~fees.~~could ~~For~~be ~~the~~significant ~~reasons~~since ~~discuss~~not ~~below,~~only ~~there~~will ~~can~~it behave noimproved ~~assurances~~its ~~that~~existing ~~the~~products ~~Company~~and ~~will~~services, bebut ~~successful~~broadened ~~at increasing~~ its ~~network~~product ofand ~~affiliated~~service ~~medical providers~~offering.

108

The other regenerative medicine opportunities the Company ~~did~~is exploring include the use of nano-technology in hair transplant and hair regrowth procedures and the use of autologous platelet rich plasma containing stem cells for joint and ligament repair. To the Company’s knowledge, written protocols applying these technologies to these uses do not ~~acquire~~yet ~~any~~exist. ~~tangible~~The ~~assets~~Company ~~from~~has ~~Biostem~~entered into USa ~~LLC~~letter orof Drintent with an R&D laboratory associated with a major U.S. ~~Markou~~university and is undertake the testing necessary to enable the Company (using its internal staff and resources as well as the assistance of the laboratory) to develop written protocols to put this technology to use in practical applications for hair transplant and hair regrowth and joint and ligament injections. The forgoing testing is not a clinical trial and the Company is not currently undertaking any clinical trials, ~~only~~including any that would require FDA approval. The Company may license certain technology on which these applications are based from the ~~intangible~~forgoing ~~assets~~university ~~related~~and the parties are in discussion regarding the terms of any such license. The Company intends to pay for the referenced license either with stock of the Company, cash or a combination of both. The Biostem Method does not require FDA approval and ~~name~~doctors providing hair transplant and hair regrowth using the Biostem Method do not require FDA approval to provide such procedures. Furthermore, the Company does not intend, at this time, to license to medical affiliates or to develop or otherwise pursue any products or services that require FDA approval.

In consideration for the Acquired Assets, the Company, at the direction of the LLC, issued 20,400,000 shares of common stock to the 11 owners of the Biostem US LLC, which resulted in the change of control of the Company, as the owners of the LLC owned approximately 95% of the 25,040,000 shares of Company common stock outstanding immediately after the Asset Transfer. As the seller of the Acquired Assets retained control of the assets through their control of the Company, the Acquired Assets were recorded at the seller’s basis of $0.

In connection with the Asset Transfer, effective May 5, 2010, the Company changed its name to Biostem U.S. Corporation and increased its authorized stock to 200,000,000 shares of common stock, par value $.001 per share.

Since the Asset Transfer, the Company has discontinued its former oil and gas business and instead has begun to pursue its marketing and licensing business focused on regenerative medicine. To this end, in June, 2011, the Company hired a new Chief Executive Officer, Dwight Brunoehler, and appointed a new board of directors. Mr. Brunoehler devotes substantially all of his business time and efforts to the Company. Among other things, since being hired, Mr. Brunoehler has reviewed the Company’s systems, protocols and processes and renegotiated the Company’s agreements with its former management. As a result, 12,013,262 shares issued as part of the Asset Transfer have been returned to the Company and cancelled. As a result of the forgoing review of the Company’s protocols and processes related to the Biostem Method, the Company has concluded that while the Biostem Method, in the form acquired by the Company, is effective and achieves positive results in hair transplants, it is unlikely that the Company will be able to patent the current Biostem Method protocols and procedures because, while the current Biostem Method is a unique arrangement and conglomeration of several discrete procedures (such as the use of low-level laser treatments and PRP injections to the affected scalp areas), no individual procedure is novel and each has previously been used in hair transplant procedures. As a result, the Company does not believe it can patent the Biostem Method in its current form and that it may not be able to prevent others from using the same or similar protocols and procedures for hair transplants. In such a case, the Company’s ability to develop a significant network of medical affiliates and its ability to charge those affiliates appropriate marketing and licensing fees could be materially negatively impacted. The Company believes its success in (a) developing a robust network of medical affiliates, (b) developing brand recognition for Biostem services and products and (c) its ability grow its regenerative medicine business depends, in part, on the value, uniqueness, protectability and effectiveness of its processes, procedures and knowhow. As such, the Company is pursuing additional protocols and procedures that could be incorporated into the Biostem Method that would not only continue to improve its effectiveness in hair transplants and other regenerative procedures, but that also would make it unique and exclusive to the Company, thus allowing it to patent and protect its proprietary property. Until such time, so that the Company can conserve cash and focus on so improving its protocols and procedures, the Company has chosen to suspend its marketing efforts and its efforts to expand its medical affiliate network.

Management estimates that the Company will be in a position to fully resume its marketing efforts and its efforts to expand its medical affiliate network once it secures additional financing of at least $2,000,000 and modifies its protocols and procedures in a manner which allows the Company to patent and protect such intellectual property, as discussed above, which management hopes to achieve before the end of June 30, 2012, although there can be no assurances in this regard. However, recently the Company’s officers and directors have been involved in private negotiations with certain foreign hair-transplant clinics interested in licensing the Company’s current hair-transplant protocols and procedures. There can be no assurances that these foreign licenses will ever come to fruition.

Until a patent is issued, the Company has been informed that its original Biostem Method can most effectively be protected with confidentiality and other appropriate agreements. The Company has entered into confidentiality or other similar agreements with each of its material suppliers and the other parties who, to its knowledge, have had access to its protocols and procedures, and it intends to continue to enter into such agreements when appropriate and necessary to protect its confidential information. Furthermore, the Company intends to file applications to register its trademark (Biostem) and any new protocols and procedures as they are developed and as cash flow allows.

Currently, the Company continues to market and sell various over-the-counter hair-support products (including oral nutriceuticals, shampoos and related items) through its website, www.biostem.us . All of these products are manufactured by third-parties based on the Company’s non-proprietary specifications on a private-label basis. The Company has recently terminated a supply agreement with one supplier, although it still purchases products from that supplier via periodic purchase orders. The Company does not have any other supply agreements but also purchases products from another supplier via periodic purchase orders. The Company is currently exploring other supply arrangements.

Most of the Company’s products purchased during this period were purchased by Dr. Markou’s patients. In the future, the Company hopes to generate revenues both through direct sales of products to consumers and from sales made through its medical affiliates, as well as from licensing, marketing and leasing fees charged to its medical affiliates. However, until the Company resumes its marketing efforts, including through radio, television and internet campaigns, it expects its sales to remain small and to be limited to the sale of products primarily through it website.

In addition to expanding and improving its hair treatment protocols and procedures, the Company also currently is working on (a) studying, exploring and pursuing other regenerative medicine opportunities, (b) protecting its intellectual property through trademark and patent registrations and (c) negotiating the potential acquisition of a non-U.S. healthcare company in the stem cell sciences business. If the Company is successful with the forgoing objectives, the changes to its current products and services could be significant since not only will it have improved its existing products and services, but broadened its product and service offering.

The other regenerative medicine opportunities the Company is exploring include the use of nano-technology in hair transplant procedures and the use of autologous platelet rich plasma containing stem cells for joint and ligament repair. To the Company’s knowledge, written protocols applying these technologies to these uses do not yet exist. The Company currently is negotiating with an R&D laboratory associated with a U.S. university to undertake the testing necessary to enable the Company (using its internal staff and resources as well as the assistance of the laboratory) to develop written protocols to put this technology to use in practical applications for hair transplants and joint and ligament injections. The forgoing testing is not a clinical trial and the Company is not currently undertaking any clinical trials, including any that would require FDA approval. The Company may license certain technology on which these applications are based from the forgoing university and the parties are in discussion regarding the terms of any such license. The Company intends to pay for the referenced license either with stock of the Company, cash or a combination of both. Any such cash used in this regard is included in the estimated $2 million we anticipate requiring in the next 12 months, as discussed further below. There can be no assurances that the Company will be successful in bringing these applications to market.

The Biostem Method does not require FDA approval and doctors providing hair transplants using the Biostem Method do not require FDA approval to provide such procedures. Furthermore, the Company does not intend, at this time, to license to medical affiliates or to develop or otherwise pursue any products or services that require FDA approval.

To assist the Company with the forgoing business plans and objectives, on July 14, 2011, the Company entered into a Consulting Agreement with NVO, LLC, a California limited liability company, pursuant to which NVO will assist the Company with its business objectives, including (i) identifying, analyzing, structuring and/or negotiating business sales and/or acquisitions, (ii) assisting the Company in its corporate strategies, (iii) assisting the Company in the implementation of its business plan, and (iv) assisting the Company in the negotiation, documentation and closing of strategic alliances, partnerships and joint ventures. In consideration thereof, the Company is making certain cash payments to NVO and issued 1,000,000 shares of restricted common stock to NVO.

~~The~~In May, 2012 the Company ~~has~~signed ~~depleted~~an ~~its~~agreement ~~cash~~with ~~and~~an ~~will~~Investors ~~require~~Relations ~~significant~~Service. ~~additional~~The ~~financing~~service towill ~~achieve~~be itinstrumental ~~business~~in ~~plans~~communicating ~~and~~with ~~objectives.~~investors ~~Over~~about the ~~next~~Company 12and ~~months,~~its ~~the~~achievements. The Company ~~anticipates~~feels itthe service will ~~require~~be ~~approximately~~beneficial ~~$2,000,000.~~to ~~While~~both the Company isand ~~exploring~~its ~~financing~~investors ~~options,~~helping ~~there~~the ~~can~~public beto nobetter ~~assurances~~understand ~~that~~the itnature ~~will~~and bescope ~~able~~of tothe ~~obtain additional financing. The~~ Company’s ~~ability~~procedures ~~to effectuate its business plans~~ and ~~objectives~~the ~~are~~market ~~subject~~for toits ~~various risks~~procedures. ~~See “Risk Factors.”~~

~~RESULTS~~The OFCompany ~~OPERATION~~has engaged a leading marketing and advertising agency to develop and assist in the execution of the communications program for marketing the Company’s process. The agency will develop the plan, create the media and implement it as it is approve by the Company. The plan will target majorcities to seek medical affiliates as well as potential patients for those affiliates. It is anticipated that the program will begin in the thrid quarter.

~~During~~On ~~the~~July ~~three and nine months period ending November 30~~1, ~~2011,~~2012 the Company ~~had~~Signed ~~revenues~~an ofaffiliate ~~$652~~contract ~~and~~with ~~$94,058, consisting of $552 in procedures by~~ a ~~related~~leading ~~party~~transplant ~~and~~clinics ~~$100~~with ofestablished ~~product~~locations ~~sales~~in ~~during the~~ three~~-month~~ ~~period~~major ~~and~~cities ~~$91,939~~in ofFlorida ~~procedures~~whereby ~~by related party and product sales of $2,119 during~~ the ~~nine-month~~clinics ~~period,~~will ~~with~~use ~~cost of goods sold of zero and $38,489, respectively, compared to no revenues and no costs of goods sold for~~ the ~~same~~Biostem ~~periods~~process in ~~2010.~~it ~~The~~treatment ~~Company’s revenues consist~~ of ~~the sale of products and fees received from its sole medical affiliate for the services it provides to him~~patients. ~~Additionally,~~In ~~the~~addition one ~~Company had general and administrative expenses~~ of ~~$260,507 and $1,771,344 for~~ the ~~three~~clinics ~~and~~will ~~nine~~serve ~~month~~as ~~period~~a ~~ending~~training ~~November~~facility ~~30,~~to ~~2011~~train ~~and~~future ~~$82,651~~affiliates ~~and~~that ~~$97,948~~associate ~~for~~with the ~~same periods in 2010~~company. The ~~dramatic~~Company ~~increase~~will ~~was~~receive ~~due~~monthly torevenue ~~the~~along ~~issuance~~with ~~of stock for services, totaling $1,130,237 during~~ the ~~period~~endorsement ~~ending November 30, 2011. The shares issued were valued as~~ of ~~the~~one ~~date~~ of ~~issuance. Net loss for~~ the ~~three~~leading ~~and~~clinics ~~nine month period ending November 30, 2011 was $259,831 and $1,715,751, compared to a net loss of $82,651 and $97,948 during the same periods~~ in ~~2010. The increase in net loss also is~~ the ~~result of the additional cost and expenses incurred for consulting and the ongoing implementation of the Company’s~~ business ~~plan~~. ~~While~~Further the ~~Company’s~~medical ~~revenues~~doctor ~~also increased as a result~~ of the ~~implementation~~clinic ofwill ~~its~~serve ~~business plan, revenues did not grow~~ as ~~quickly as~~ the ~~Company’s~~Medical ~~costs~~Director ~~and~~of ~~expenses~~Biostem.

The Company has depleted its cash and required significant additional financing to achieve it business plans and objectives. As a result, the Company entered into a stock purchase agreement with Elco Securities Ltd. (“Elco”), pursuant to which the Company agreed to sell to Elco, and Elco agreed to purchase from the Company, 20,000,000 shares of common stock of the Company for an aggregate purchase price of $5,000,000, which amount is payable in six equal monthly installments. The stock purchase agreement provides that the closing of the forgoing transaction will occur on July 1, 2012 or at such other time as the parties may agree.

The Company’s ability to effectuate its business plans and objectives are subject to various risks. See “Risk Factors.”

RESULTS OF OPERATIONS

During the three months period ended May 31, 2012, the Company had revenues of $624 with cost of goods sold of zero, compared to $87,670 revenues and $38,435 in costs of goods sold for the same period in 2011. The Company’s revenues consisted of fees received from its sole medical affiliate for the services it provides to him. Additionally, the Company had general and administrative expenses of $884,361 for the three month period ended May 31, 2012 compared to $212,030 for the same period in 2011. The dramatic increase was due to the issuance of stock for services, totaling $664,373 during the period ended May 31, 2012. The shares issued were valued monthly over the vesting period. Net loss for the three month period ended May 31, 2012 was $883,729 compared to a net loss of $162,795 during the same period in 2011. The increase in net loss also is the result of the additional cost and expenses incurred for consulting and the ongoing implementation of the Company’s business plan.

LIQUIDITY AND CAPITAL RESOURCES

At the ~~nine~~three month period ended ~~November~~May 3031, ~~2011~~2012, the Company’s current assets were $3115,~~446~~683 and its current liabilities were $~~112~~309,~~879~~453, which resulted in negative working capital of $81293,~~433~~769. Stockholders’ deficit was $81293,~~433~~770 for the period ended ~~November~~May 3031, ~~2011~~2012, compared to ~~shareholders~~a ~~equity~~deficit of $~~257~~74,~~981~~414 as of February 2829, ~~2011~~2012. The Company anticipates that its working capital requirements will continue to increase as it implements its business plans, acquires inventory and equipment, undertakes increased marketing and explores other regenerative healthcare opportunities. Since the end of the quarter covered by this Form 10-Q, the Company has depleted its cash and will require significant additional financing to achieve it business plans and objectives. Over the next 12 months, the Company anticipates it will require approximately $2,000,000. While the Company is exploring financing options, there can be no assurances that it will be able to obtain additional financing. The Company’s ability to effectuate its business plans and objectives are subject to various risks. See “Risk Factors.”

Cash Flows from Operating Activities

For the ~~nine~~three month period ended ~~November~~May 3031, ~~2011~~2012 and ~~2010~~2011, net cash flows used in operating activities were $~~530~~225,~~635~~221 in ~~2011~~2012 and $~~102~~174,~~880~~158, respectively. The increase is the result of the additional cost and expenses incurred in connection with the ongoing implementation of the Company’s business plan. ~~While the Company’s revenues increased, revenues did not cover the Company’s costs and expenses.~~

Cash Flows from Financing Activities

The Company issued ~~637,500~~notes ~~shares~~to oftwo ~~common~~related ~~stock~~parties ~~with~~totaling ~~a value of~~ $~~246~~225,000 during the ~~nine~~three-month period ended ~~November~~May 3031, ~~2011~~2012. For the ~~nine~~three month period ending ~~November~~May 3031, ~~2011~~2012, net cash provided by financing activities was $~~246~~225,000 compared to ~~$503,157~~zero for the same period in ~~2010~~2011.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required under this Item.

ITEM 4: CONTROLS AND PROCEDURES

This report includes the certifications of our Chief Executive Officer and Chief Financial Officer required by Rule 13a-14 under the Securities Exchange Act of 1934 (the "Exchange Act"). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the Principal Executive Officer and the Principal Financial Officer, to allow timely decisions regarding required disclosures.

14In connection with the preparation of this report, our management, under the supervision and with participation of our Principal Executive Officer and Principal Financial Officer (the “Certifying Officers”) conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of May 31, 2012. Based on that evaluation, our management concluded that there is a material weakness in our disclosure controls and procedures over financial reporting. The material weakness results from a lack of written procedures which effectively documents the proper procedures and descriptions of the duties of all persons involved in the disclosure controls of the Company. The Company hopes to implement plans to document the procedures and internal controls of the Company. A material weakness is a deficiency, or a combination of control deficiencies, in disclosure control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. This does not include an evaluation by the Company’s registered public accounting firm regarding the Company’s internal control over financial reporting.

In connection with the preparation of this report, our management, under the supervision and with participation of our Principal Executive Officer and Principal Financial Officer (the “Certifying Officers”) conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, 2011. Based on that evaluation, our management concluded that there is a material weakness in our disclosure controls and procedures over financial reporting. The material weakness results from a lack of written procedures which effectively documents the proper procedures and descriptions of the duties of all persons involved in the disclosure controls of the Company. The Company hopes to implement plans to document the procedures and internal controls of the Company. A material weakness is a deficiency, or a combination of control deficiencies, in disclosure control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. This does not include an evaluation by the Company’s registered public accounting firm regarding the Company’s internal control over financial reporting.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our first quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Our management believes that the Unaudited ~~Condensed Consolidated~~ Financial Statements included herein present, in all material respects, the Company’s financial condition, results of operations and cash flows for the periods presented.

1511

PART II: OTHER INFORMATION

ITEM 1: LEGAL PROCEEDINGS

None

RISKS RELATED TO OUR BUSINESS:

The Company has a limited operating history upon which you can evaluate its business and its business model continues to evolve.

The Company ~~remains a development stage Company with a limited operating history. The Company~~’s past operating history may not provide an adequate gauge of its potential for growth and future profitability. The limited amount of information about the Company makes it more difficult for you to predict whether or not the Company will be successful. You should evaluate the Company’s chances of financial and operational success in light of the risks, uncertainties, expenses, delays and difficulties associated with starting a new business, many of which may be beyond the Company’s control. In addition to the uncertainties involved in developing, managing and maintaining a business of the type proposed by the Company, there are a number of other risk factors customarily associated with the commencement of any new business that can reduce the funds available for the initial operations of the enterprise. In the event of cost overruns, or in the event ~~that~~those other contingencies arise, the Company may require additional capital or financing, which may not be available on terms acceptable to the Company or at all.

To date, the Company has only incurred losses and it is expected it will continue to incur losses in the immediate future and it currently has depleted its cash reserves, which raise significant doubt about its ability to continue as a going concern.

The Company has incurred losses since inception and has depleted its cash reserves. Additionally, the Company recently has suspended its hair transplant and hair regrowth marketing efforts, which saves cash but also is expected to materially negatively impact its revenues. The Company will require significant funds to develop and implement its business plans. All these facts raise significant doubts about the Company’s ability to continue as a going concern.

The Company has limited revenues and will need additional financing.

The Company needs additional capital to develop and implement its business plans. Over the next 12 months, the Company anticipates it will require approximately $2,000,000, which, because of its limited revenues, will primarily need to come from additional financing. The sources of such additional capital could include loans from financial institutions and the offer and sale of additional shares of Common Stock or preferred stock by the Company. However, it is highly unlikely that the Company will qualify for any traditional lending at this time or in the near future. Furthermore, no assurance can be made that any existing shareholders or other sources of capital will be willing to invest additional capital or make additional loans to the Company. Further, any sale of additional shares may substantially dilute the ownership the Company’s current shareholders. If the Company is unable to obtain additional financing, its growth will be hampered and it may not be able to continue as a going concern.

The Company has issued shares to a consultant which could have a material negative impact on its income from continuing operations.

As discussed above, on July 14, 2011, the Company entered into a one-year Consulting Agreement with NVO, LLC, pursuant to which the Company is making certain cash payments to NVO and has issued 1,000,000 shares of restricted common stock to NVO, 250,000 of which vested immediately on July 14, 2011 and the balance of which vests in 18 monthly installments of 41500,~~666.67~~000 commencing on January 14, 2011. The ~~250~~3,000,000 shares which have vested were measured and recognized as expense during the quarter ending August 31, 2011, resulting in an expense of $750,000. The remaining ~~750~~9,000,000 shares will be measured and expensed at the completion of each month during the remaining 18-month vesting period based on the price of the Company’s stock price during such period, which will result in future expenses that will fluctuate based on the stock price in each future month during the vesting period. As a result of the Company’s light trading volume and its volatile stock price, the total expense associated with these shares is uncertain, but could be significant. ~~Over~~The ~~the last year, the Company’s stock price has traded between $4.00 and $0.06. Thus, at the high end of this range, the~~ total expense for the remaining ~~750~~9,000 ~~shares would be $3~~,000~~,000,~~ ~~which~~shares could have a material unfavorable impact on income from continuing operations. Additionally, as these shares vest the Company’s existing shareholder will incur dilution of their percentage ownership in the Company.

Unfavorable general economic conditions could negatively impact our operating results and financial condition.

While it is often difficult to predict the impact of general economic conditions on our business, these conditions could adversely affect the demand for our products and services. Generally, these products and services are not covered by health insurance or Medicare or Medicaid and, accordingly, customers and patients must pay for them with cash. Accordingly, a decline in the economy, or even a perceived or anticipated decline, could cause a decline in the demand for those products and services.

We will incur additional expenses as a result of being a reporting public company, which may further strain our limited resources.

We expect to continue to incur significant expenses as a result of being a reporting company, including increased legal and accounting expenses and expenses incurred in complying with the internal controls requirements of the Sarbanes Oxley Act. Currently, the Company estimates that the total amount of these additional expenses approximates $250,000. Our failure to generate sufficient revenue and gross profit could result in reduced profits or increased losses as a result of the additional expenses.

The Company may not be able to protect its processes, procedures and knowhow and the worth of such processes, procedures and knowhow is uncertain.

The Company has not attempted to register its trademark (Biostem) and it does not believe it can receive patent protection on its current Biostem Method processes, procedures and knowhow for the reasons discussed in Section 1 above. As a result, the Company may not be able to enjoin or otherwise restrict the ability of any other person from using intellectual property, procedures or knowhow that are the same or similar to those of the Company, which may limit the Company’s ability to develop its network of medical affiliates and negatively impact its revenues.

Our growth strategy is dependent in part on developing a network of affiliated medical providers.

While the Company intends to sell certain products directly to consumers and hair transplant and hair regrowth clinics, it will not perform any medical procedures. Instead, the Company intends to market the Biostem procedures and develop a network of qualified medical providers that will perform the ~~such~~ procedures on their patients. Accordingly, the Company’s growth and revenues will depend on revenue generated by its affiliated medical providers. Currently the Company does not have any formal agreements with any medical providers. The Company believes its success in (a) developing a robust network of medical affiliates, (b) developing brand recognition for Biostem services and products and (c) its ability grow its hair transplant and hair regrowth business depends, in part, on the value and effectiveness of its hair transplant and hair regrowth processes, procedures and knowhow. As discussed further above, the Company does not believe it can secure patent protection for its current Biostem Method process and protocols. Currently, the Company is undertaking a re-evaluation of its current hair transplant processes, procedures and knowhow and is exploring related opportunities. There can be no assurances that the Company will be successful at developing or maintaining effective processes, procedures and knowhow or in increasing its network of affiliated medical providers.

We are dependent on certain officers of the Company.

Dwight C. Brunoehler, our CEO, is actively engaged in growing and managing our business. The loss of any of Mr. Brunoehler could adversely and materially impact the Company.

~~Our President and CFO, and one of our directors, John Satino, is involved in another business which may cause him to devote less time to our business and may create certain conflicts of interest.~~13

Until the Company is prepared to significantly increase its marketing efforts, which is not expected to occur until the Company can obtain additional financing and until it strengthens and expands its product and service offerings, Mr. Satino’s duties to the Company are limited. The Company currently is not dependent on him. Furthermore, Mr. Satino’s employment agreement with the Company places certain restriction on him. Among other things, he has agreed not to enter into any relationship with, or solicit, divert, or attempt to solicit or divert from the Company, any vendors, suppliers or customers of the Company, or to disrupt, damage, impair or interfere with the business of the Company. And he has also agreed to keep the Company’s confidential information confidential and has assigned all rights he may have to the Biostem Method, if any, or to any improvements thereto to the Company. The forgoing notwithstanding, by reason of the fact that Mr. Satino also is President of Biotone Corporation, d/b/a hair and scalp clinics, a hair replacement company, to which he currently devotes most of his business time and efforts, a conflict of interest could arise with regard to Mr. Satino and he may not be able to devote sufficient attention to the Company once it is ready to significantly increase its marketing efforts, which could affect our operations and profitability.

Our success depends, in part, on the quality of our products and services.

Our success depends, in part, on the quality of our products and services. If our products and services are found to be defective or unsafe, or if they otherwise fail to meet our medical affiliates’ standards, our relationships with our medical affiliates could suffer, our brand appeal could be diminished, and we could lose market share and/or become subject to liability claims, any of which could result in a material adverse effect on our business, results of operations and financial condition.

We may be subject to various regulations, including health care laws.

The health care industry is highly regulated, with each state and the federal government imposing its own requirements. Among other things, most states prohibit corporations that are not owned exclusively by medical professionals from providing medical services and procedures. Furthermore, most states have laws prohibiting paying or receiving any remuneration, direct or indirect, that is intended to induce referrals for health care products or services. Many states also prohibit “fee-splitting” by medical professionals with any party except other medical professionals in the same professional corporation or practice association. In most cases, these laws apply to the paying of a fee based on a percentage of the practice’s revenues to another person for referring a patient or otherwise generating business, and do not prohibit payment of reasonable compensation for facilities, equipment and other services. The Company intends to comply with all applicable health care regulations on a state-by-state basis, starting with Florida and expanding into other states as the Company grows. With the assistance of health care counsel, before entering a state, the Company will analyze the state rules and regulations and endeavor to structure its financial and business arrangements with medical providers in each state in which the Company operates in a manner that complies with that state’s regulations. Without limiting the forgoing, the Company will only provide such services and support to its medical affiliates, including paid support staff to assist with medical procedures, if allowed by the rules and regulations of such state. This analysis may be expensive and time consuming and the restrictions imposed by applicable laws and regulations may negatively impact the Company’s profitability. Further, there can be no assurance that the regulatory environment in which the Company operates will not change significantly and adversely in the future. Monitoring and compliance with such regulations will increase the operating expenses of the Company.

We are subject to competition.

The Company expects to encounter well-established competitors with substantially greater financial and other resources than the Company. Some of the Company’s competitors have been in existence for a substantially longer period than the Company and may be better established in the markets where the Company may be located.

RISKS RELATING TO OUR COMMON STOCK:

The Company has a large number of shares outstanding and a very light trading volume.

The Company has 85,056,952 shares of common stock issued and outstanding, and most of the Company’s shareholders are not subject to any contractual restrictions on their ability to sell shares. Meanwhile, the Company has an extremely light trading volume. As a result, any attempt to sell anything more than a nominal amount of shares will significantly negatively impact the stock’s trading price, and shareholders may not be able to sell their shares at prices they desire, or at all, and they may need to hold their shares for the indefinite future. A more robust trading volume may never develop. This will also make it difficult for the Company to use its shares to pay for services or products or in connection with mergers and acquisitions.

Fluctuations in our operating results and announcements and developments concerning our business affect our stock price.

Our quarterly operating results, the number of stockholders desiring to sell their shares, changes in general economic conditions and the financial markets, the execution of new contracts and the completion of existing agreements and other developments affecting us, could cause the market price of our common stock to fluctuate substantially.

We are not required to meet or maintain any listing standards for our common stock to be quoted on the OTCQB, which could affect our stockholders’ ability to access trading information about our stock.

OTC Markets is separate and distinct from the NASDAQ Stock Market and any national stock exchange, such as the New York Stock Exchange or the American Stock Exchange. Although the OTCQB is a regulated quotation service operated by the OTC Markets that displays real-time quotes, last sales prices, and volume information in over-the-counter (OTC) equity securities like our Common Stock, we are not required to meet or maintain any qualitative or quantitative standards for our Common Stock to be quoted on the OTCBB. Our Common Stock does not presently, and may never,; meet the minimum listing standards for listing on the NASDAQ Stock Market or any national securities exchange.

If we cease filing periodic reports with the SEC, the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market would be negatively impacted.

If we cease filing periodic reports with the SEC, it will affect our stockholders’ ability to access trading information about our Common Stock and the Company will no longer qualify for quotation on the OTCQB and will instead be eligible only for quotation on the Pink Sheets, which could negatively impact our stock price and the liquidity of our Common Stock. Companies trading on the OTCQB, such as us, must be current in their SEC reports to maintain price quotation privileges on the OTCQB. The Company currently is not required to file periodic reports with the SEC.

Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and operating results and stockholders could lose confidence in our financial reporting.

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework. Based on its evaluation, our management concluded that there is a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. This does not include an evaluation by the Company’s registered public accounting firm regarding the Company’s internal control over financial reporting.

The Company has concluded the weakness is a result of a lack of written procedures which effectively document the proper procedures and descriptions of the duties of all persons involved in the internal controls of the Company. The Company hopes to implement plans to document the procedures and internal controls of the Company.

Our directors and executive officers and affiliates beneficially own approximately 26.68 % of our Common Stock; their interests could conflict with yours; significant sales of stock held by them could have a negative effect on our stock price; stockholders may be unable to exercise control.

As of June 23, 2011, our executive officers, directors and affiliates beneficially owned approximately 26.68 % of our Common Stock. As a result, our executive officers, directors and affiliates will have significant influence to:

• elect or defeat the election of our directors; • amend or prevent amendment of our articles of incorporation or bylaws; • effect or prevent a merger, sale of assets or other corporate transaction; and • control the outcome of any other matter submitted to the stockholders for vote.

In addition, sales of significant amounts of shares held by our directors, executive officers and affiliates, or the prospect of these sales, could adversely affect the market price of our Common Stock. Management’s stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price.

Because we may be subject to the “penny stock” rules, you may have difficulty in selling our Common Stock.

Our stock currently is subject to the SEC’s penny stock rules, which impose additional sales practice requirements and restrictions on broker-dealers that sell our stock to persons other than established customers and institutional accredited investors. The application of these rules may affect the ability of broker-dealers to sell our Common Stock and may affect your ability to sell any Common Stock you may own. According to the SEC, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include:

	•	Control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer;
	•	Manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases;
	•	“Boiler room” practices involving high pressure sales tactics and unrealistic price projections by inexperienced sales persons;
	•	Excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and
	•	The wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.

ITEM 2: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~During the period ended November 30, 2011, the Company sold 577,500 shares of restricted common stock to seven individuals for an aggregate cash payment of $231,000.~~None

During the period ending November 30, 2011, the Company issued 1,600,000 shares of restricted common stock to an officer as part of the officer’s employment contract with the Company. The shares vest over a 36-month period, with the 266,670 having vested as of November 30, 2011.

During the period ended November 30, 2011, the Company issued 1,000,000 to NVO, LLC as consulting fees pursuant to a Consulting Agreement with NVO, LLC, as discussed further above.

The Company claims an exemption from the registration requirements of the Securities Act of 1933 (the “Act”) for the issuance of all the securities discussed above pursuant to Section 4(2) of the Act and/or Regulation D promulgated thereunder since, among other things, the transactions did not involve a public offering, the investors were accredited investors and/or qualified institutional buyers, the investors had access to information about the Company and their investment, the investors took the securities for investment and not resale, and the Company took appropriate measures to restrict the transfer of the securities.

ITEM 3: DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4: [REMOVED AND RESERVED]

ITEM 5: OTHER INFORMATION

None

6.ITEM 6: EXHIBITS

Exhibits:

31.1 Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

31.1	Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

31.2	Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

32.1	Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d- 14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

31.2 Certification of Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

32.1 Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d- 14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

101.INS **		XBRL Instance Document

101.SCH **		XBRL Taxonomy Extension Schema Document

101.CAL **		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF **		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB **		XBRL Taxonomy Extension Label Linkbase Document

101.PRE **		XBRL Taxonomy Extension Presentation Linkbase Document

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

2217

SIGNATURES

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Biostem U.S. Corporation
Dated: January 17, 2012	By:	/s/ Dwight Brunoehler
Dated: July 12, 2012	By:	/s/ Dwight Brunoehler
		John Dwight Brunoehler
		John Dwight Brunoehler,
		Chief Executive Officer
Dated: July 12, 2012	By:	/s/ John Satino
		John Satino,
		Chief Financial Officer

Dated January 17, 2011	By:	/s/ John Satino
		John Satino
		Chief Financial Officer

Filing Compare · BIOSTEM U.S. CORP